The right drug for every patient. The right patient for every drug.

 
Our comprehensive portfolio
of NGS-based services can be
tailored to your needs

Read more

Analyse data with our
genomics/oncogenomics
pipeline

Read more

A truly personalised approach
to cancer diagnostics and
therapy

Read more

Virtual disease models for
the prediction of treatment
response and side-effects

Read more

 

 
 

Who are we?

Alacris Theranostics GmbH is a Berlin-based company that teams cutting-edge molecular analysis and sophisticated bioinformatics with a revolutionary systems medicine modelling approach (ModCellTM), to better match patients to therapies (‘virtual patients’) and therapies to patients (‘virtual clinical trials’). Alacris is applying ModCellTM predictive technology for simulation of patient response to drugs, facilitating the translation of personalised medicine approaches for clinical application, and opening up new possibilities for drug development and approval pipelines in the pharmaceutical industry through implementation of ‘virtual clinical trials’. Alacris works closely together with clinics and medical professionals as well as industry leaders and researchers from the fields of personalised medicine, biomarker application, and drug development.
Read more
 

Why Alacris Theranostics?

Human beings are unique, and so are their diseases, often resulting in drastic differences in response to the same therapy. In the case of cancer, the problem is exacerbated by the uniqueness of each individual tumour. A more personalised approach to diagnosing and treating diseases is therefore required. Predicting the likely response (including side effects) of a specific patient to different therapies relies on a detailed molecular analysis of the patient’s genome and his/her unique tumour. This deep molecular characterisation not only facilitates identification of changes in a tumour that can be directly linked to treatment options (so called ‘actionable variants’) but also provides essential information for construction of an in silico model of individual tumours using ModCellTM. By providing the possibility to systematically test the effect of administering hundreds of different drugs or drug combinations in silico, rather than a limited range on the patient directly, ModCellTM helps focus treatment strategy, reducing drug side effects and ultimately increasing the likelihood of a successful outcome.
Read more
 

What can we do for you?

Whether you are a patient, doctor, hospital, pharmaceutical company, researcher or concerned individual, our services will provide key data and insight for a range of potential applications. Alacris provides extensive bioinformatics expertise and state-of-the-art facilities including a next generation sequencing lab for clinical application, certified to highest quality standards, and a powerful and secure IT infrastructure.
Read more
 

To discuss your project requirements, please contact us